Aimad Torqui

Background

About Aimad Torqui

As a Division Head at the Medicines Evaluation Board (MEB) and a member of its executive management team since 2022, I drive national and European policy initiatives, regulatory science advancements, and strategic efforts to enhance medicine use. My portfolio also includes veterinary medicines and collaboration on European-level regulatory frameworks. I represent the Netherlands as an alternate member on the EMA Management Board and contribute to the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), shaping policies to ensure medicine availability and safety across Europe. With over 15 years of experience spanning government and industry, I have developed a deep expertise in regulatory affairs, policy development, and stakeholder engagement. I began my career at the MEB in 2006 as a regulatory case manager, progressing through multiple roles before being appointed as the alternate member to CMDh in 2010. In 2013, I transitioned into the pharmaceutical industry, where I gained hands-on experience as a regulatory affairs manager and later as a regional lead for global regulatory policy, strengthening my insights into industry perspectives and global regulatory dynamics. My academic background in biotechnology (HAN University of Applied Sciences) and molecular biology (Radboud University Nijmegen) underpins my scientific and regulatory expertise. I am passionate about bridging regulatory science and policy to drive innovation, improve medicine access, and strengthen collaboration between agencies, industry, and healthcare stakeholders.